Metastatic Squamous Cell Carcinoma Clinical Trials

3 recruiting

Metastatic Squamous Cell Carcinoma Trials at a Glance

7 actively recruiting trials for metastatic squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Amsterdam, Barcelona, and Bellinzona. Lead sponsors running metastatic squamous cell carcinoma studies include European Organisation for Research and Treatment of Cancer - EORTC, Groupe Oncologie Radiotherapie Tete et Cou, and Centre Hospitalier Universitaire de Besancon.

Browse metastatic squamous cell carcinoma trials by phase

Treatments under study

About Metastatic Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Metastatic Squamous Cell Carcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck
Washington University School of Medicine46 enrolled1 locationNCT07419464
Recruiting
Phase 3

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled26 locationsNCT05815927
Recruiting
Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Shanghai Miracogen Inc.116 enrolled1 locationNCT04868162
Recruiting
Phase 2

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Groupe Oncologie Radiotherapie Tete et Cou70 enrolled1 locationNCT06640725
Recruiting
Phase 2

Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Squamous Cell Anal CarcinomaMetastatic Squamous Cell Carcinoma
Centre Hospitalier Universitaire de Besancon34 enrolled5 locationsNCT04894370
Recruiting
Phase 2

Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy

Metastatic Squamous Cell Carcinoma of the Vulva
The Netherlands Cancer Institute12 enrolled1 locationNCT04161664